Adoptive transfer of anti-CD3-activated CD4+ T cells plus cyclophosphamide and liposome-encapsulated interleukin-2 cure murine MC-38 and 3LL tumors and establish tumor-specific immunity.

The infusion of anti-CD3-activated murine T cells plus interleukin-2 (IL-2) exerts antitumor effects against several tumors in murine immunotherapy models. This study compares the therapeutic efficacy of anti-CD3-activated CD4+ or CD8+ T-cell subsets, when given with cyclophosphamide (Cy) and liposome-encapsulated IL-2 (L-IL2) in a murine model. C57BL/6 mice bearing subcutaneous (S.C.) MC-38 colon adenocarcinoma, 3LL Lewis lung carcinoma, or 38C13 lymphoma for 7 to 14 days were pretreated with low-dose intraperitoneal (I.P.) Cy before intravenous (I.V.) injection of anti-CD3-activated T cells or T-cell subsets. Cell administration was followed by I.P. administration of L-IL2 for 5 days. Mice receiving activated CD4+ T cells showed significantly reduced tumor growth or complete remissions with prolonged disease-free survival in MC-38, 3LL, and 38C13. The timing of Cy doses in relation to adoptive transfer was critical in obtaining the optimal antitumor effect by CD4+ cells. Injecting Cy 4 days before the infusion of CD4+ cells greatly enhanced the antitumor effect of the CD4+ cells and improved survival of the mice compared with other Cy regimens. C57BL/6 mice cured of MC-38 after treatment with CD4+ T cells developed tumor-type immunologic memory as demonstrated by their ability to reject rechallenges with MC-38, but not 3LL. Similarly, mice cured of 3LL tumors rejected rechallenges of 3LL, but not MC-38. The immunologic memory could be transferred with an I.V. injection of splenocytes from mice cured of MC-38 or 3LL. No cytotoxic T-lymphocyte activity was detected in T cells or T-cell subsets from mice cured of MC-38 or 3LL. Increased IL-2 and interferon-gamma (IFN-gamma) production was observed from CD4+ subsets in cured animals when stimulated in vitro with the original tumor, but not with an unrelated syngeneic tumor. These results suggest that tumor-specific immunity can be achieved in vivo with anti-CD3-stimulated CD4+ T cells in this cellular therapy model.

[1]  S. Rosenberg,et al.  Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[2]  S. Rosenberg,et al.  Melanoma‐specific CD4+ T lymphocytes recognize human melanoma antigens processed and presented by epstein‐barr virus‐transformed B cells , 1994, International journal of cancer.

[3]  D. Longo,et al.  Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. , 1993, Cancer research.

[4]  M. Matsuda,et al.  Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. , 1993, Cancer research.

[5]  D. Longo,et al.  Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  D. Longo,et al.  Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. , 1992, Science.

[7]  A. Chang,et al.  Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2-activated tumor-draining lymph node cells. , 1992, Cancer research.

[8]  D. Longo,et al.  Antitumor effects of interleukin 2 liposomes and anti-CD3-stimulated T-cells against murine MCA-38 hepatic metastasis. , 1991, Cancer research.

[9]  Y. Yun,et al.  In vivo antitumor activity of anti-CD3-induced activated killer cells. , 1989, Cancer research.

[10]  P. Anderson,et al.  Anti-CD3 + IL-2-stimulated murine killer cells. In vitro generation and in vivo antitumor activity. , 1989, Journal of immunology.

[11]  P. Anderson,et al.  Lymphokine-activated killer activity in long-term cultures with anti-CD3 plus interleukin 2: identification and isolation of effector subsets. , 1989, Cancer research.

[12]  D. Liggitt,et al.  Therapeutic and toxic activity of tumor necrosis factor is synergistic with gamma interferon. , 1989, Pathology and immunopathology research.

[13]  L. Matis,et al.  Adoptive chemoimmunotherapy of murine leukemia with helper T lymphocyte clones. , 1987, Journal of immunology.

[14]  F. Bach,et al.  Long-term growth of lymphokine-activated killer (LAK) cells: role of anti-CD3, beta-IL 1, interferon-gamma and -beta. , 1987, Journal of immunology.

[15]  S Guo,et al.  An interactive computer program for the analysis of growth curves. , 1987, Computers and biomedical research, an international journal.

[16]  J A Koziol,et al.  VARCOV: a computer program for the distribution-free analysis of growth and response curves. , 1984, Computer programs in biomedicine.

[17]  P. Engstrom,et al.  Augmentation of the human immune response by cyclophosphamide. , 1982, Cancer research.

[18]  I. Fidler,et al.  Enhanced metastatic potential of tumor cells harvested from spontaneous metastases of heterogeneous murine tumors. , 1982, Journal of the National Cancer Institute.

[19]  R. North.  Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells , 1982, The Journal of experimental medicine.

[20]  J. Koziol,et al.  A distribution-free test for tumor-growth curve analyses with application to an animal tumor immunotherapy experiment. , 1981, Biometrics.

[21]  Y. Bergman,et al.  Characterization of a carcinogen‐induced murine B lymphocyte cell line of C3H/eB origin , 1977, European journal of immunology.

[22]  M. Lipkin,et al.  Induction of adenocarcinomas of the colon in mice by weekly injections of 1,2-dimethylhydrazine. , 1973, Cancer research.